AstraZeneca and Daiichi Sankyo's Dato-DXd failed to improve survival in a breast cancer study. Gilead Sciences' Kite will bow ...

Gilead Sciences’ Kite Pharma will sell its stake in China’s Fosun Kite Biotechnology nearly eight years after forming the 50-50 cell-therapy-focused joint venture with Fosun Pharma.

As cell therapies continue to advance, the need for better automated, large-scale manufacturing options increases.

LAST YEAR: NEW CHANGE: NA AGE: 75 RESIDENCE: Bel Air SOURCE OF WEALTH: Pharmaceutical company sales ...

The new CEO — formerly of Kite Pharma and Genentech — will receive an annual salary of $625,000 plus a one-time bonus of $650,000. Peter Maag, who led cell therapy company Kyverna Therapeutics ...

Discover the top biotech companies pioneering the next healthcare breakthroughs. Learn how innovative firms are ...

Shanghai Fosun Pharma announced plans to buy out its JV partner, Kite Pharma, gaining full control of the JV’s two CAR-T products in China. Organon China, a women’s health company, acquired ...

Its investment in CAR-T drugs is part of that ambitious push, and 2017 is set to be a decisive year for Novartis and main rival, Kite Pharma, who lead this hugely promising but risky field.

Gilead Sciences' cell therapy Kite Pharma has bulked up its position in natural killer (NK) cell therapies, pledging up to $2.3 billion for a partnership with Shoreline Bioscience focusing on off ...

He’s been replaced by Warner Biddle, a longtime Genentech executive who has spent the last four years in senior commercial roles at Kite Pharma, Gilead’s cancer cell therapy division.

Most recently, he served as Senior Vice President, Global Head of Commercial at Kite Pharma (a Gilead Company). In this role, Mr. Biddle led multiple product launches and market-building ...

Arcellx’s strategic partnership with Kite Pharma validates its technology, potentially leading to milestone payments of up to $935 million. Anito-cel’s Phase 3 trial results are expected by ...